EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

TheStreet Wire

GlaxoSmithKline Stock To Go Ex-dividend Tomorrow (GSK)

By TheStreet Wire 11/13/12 - 09:53 AM EST

Find out if (GSK) is in Cramer's Portfolio.

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK (TheStreet) -- The ex-dividend date for GlaxoSmithKline (NYSE:GSK) is tomorrow, November 14, 2012. Owners of shares as of market close today will be eligible for a dividend of 58 cents per share. At a price of $42.83 as of 9:30 a.m. ET, the dividend yield is 5.3%.

The average volume for GlaxoSmithKline has been two million shares per day over the past 30 days. GlaxoSmithKline has a market cap of $109.95 billion and is part of the health care sector and drugs industry. Shares are down 4.6% year to date as of the close of trading on Monday.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. The company has a P/E ratio of 13.1, below the S&P 500 P/E ratio of 17.7.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. You can view the full GlaxoSmithKline Ratings Report.

See our dividend calendar or top-yielding stocks list.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.

For more information on GlaxoSmithKline PLC click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Real Money

TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:

Jim Cramer + 20 Wall Street pros
Intraday commentary & news
Real-time trading forum
Actionable trade ideas

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.